TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Teladoc Health Inc (TDOC) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are some positive technical indicators and potential for short-term gains, the company's financial performance, negative catalysts, and mixed analyst sentiment suggest caution. Holding or exploring other opportunities may be more prudent.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is at 79.044, which is in the neutral zone but nearing overbought territory. Moving averages are converging, suggesting indecision in the market. Current price is near resistance levels (R1: 5.707, R2: 5.91), which may limit further upside in the short term.
Deutsche Bank and BofA have recently upgraded the stock with higher price targets, citing undervaluation and potential for stabilization in the BetterHelp business. The MACD and technical indicators show short-term bullish momentum.
Recent news highlights concerns over poor earnings outlook and governance issues. Analysts have mostly lowered price targets, and the stock has underperformed the market. Financial performance shows declining net income, EPS, and gross margin, raising concerns about long-term profitability.
In Q4 2025, revenue increased marginally by 0.28% YoY to $642.27M, but net income dropped significantly by 48.06% YoY to -$25.14M. EPS fell by 50% YoY to -$0.14, and gross margin declined by 3.5% YoY to 54.55%. These metrics indicate weak financial health and profitability.
Analyst sentiment is mixed. Deutsche Bank and BofA have upgraded the stock, citing undervaluation and potential growth. However, several firms, including Barclays, Citi, and UBS, have lowered price targets, reflecting concerns about the company's competitive position and financial outlook.
